Angelini Labopharm joint venture launches Oleptro

Labopharm (TSX:DDS; NASDAQ:DDSS) and its joint venture partner Gruppo Angelini have launched Oleptro, an once-daily formulation of the antidepressant trazodone, in the U.S. “The commercialization strategy for Oleptro is based on extensive research into the physician, patient and payer audiences and employs a targeted, efficient sales effort that is designed to maximize the return on [...]

Labopharm amends loan accord with Hercules

Hercules Technology Growth Capital has agreed to extend both the period of interest-only payments and maturity date of a loan to Labopharm (TSX:DDS; NASDAQ:DDSS), which will provide Labopharm with $4.5 million in additional liquidity in 2010 and throughout 2011. Under the amended agreement, Hercules has extended the period for Labopharm to make interest-only payments on the [...]

Analysts cut Labopharm price targets on marketing deal

After weighing the pros and cons of Labopharm’s joint venture marketing accord with Italy’s Gruppo Angelini, Dundee Securities and Versant Partners cut their price targets on “buy-rated” Labopharm (TSX: DDS; NASDAQ: DDSS), with Dundee moving the target down to $2.40 from $3 and Versant down to $2.50 from $3. Dundee analyst David Martin cited “increased [...]